Tmunity Therapeutics Incorporated

Tmunity Therapeutics Incorporated was a clinical-stage biotechnology company based in Philadelphia, PA, founded in 2015 by innovators from the University of Pennsylvania.

The company focused on advancing cell therapy research into clinical treatments for cancer patients, particularly those with unmet medical needs. Tmunity specialized in developing next-generation CAR-T cell therapies and related technologies aimed at treating hematologic malignancies and advanced solid tumors. The company's pipeline included several preclinical candidates targeting various cancers, such as anti-mesothelin CAR-T for lung cancer and CD33HSC/CD33 CAR-T for acute myeloid leukemia. Tmunity also worked on innovative manufacturing processes for engineered T-cell therapies. In 2022, Tmunity was acquired by Kite, a Gilead Company, to enhance its cell therapy pipeline and research capabilities. Following the acquisition, Tmunity's founders became senior scientific advisors at Kite.